- 1 Title: Prevalence of Fetal Alcohol Spectrum Disorder (FASD) in Greater Manchester,
- 2 UK: an active case ascertainment study
- 4 Robyn McCarthy MSc<sup>1</sup>, Raja A.S. Mukherjee PhD<sup>1,2</sup>, Kate M. Fleming PhD<sup>3</sup>,
- 5 Jonathan Green FRCPsych <sup>4</sup>, Jill Clayton-Smith MD<sup>5</sup>, Alan D. Price PhD<sup>1</sup>, Clare S.
- 6 Allely PhD<sup>1</sup>, Penny A. Cook PhD\*<sup>1</sup>
- 7 \*Correspondence to: Penny A. Cook
- 8 School of Health and Society,
- 9 University of Salford,
- 10 Allerton Building

15

16

- 11 Frederick Road
- 12 Salford M6 6PU
- 13 p.a.cook@salford.ac.uk
- 14 Tel: +44(0)161 295 2804
- 17 1. School of Health and Society, University of Salford, UK
- Alcohol Spectrum Disorder Service, Surrey & Borders NHS Trust, UK School of
- Health and Society, University of Salford, UK
- 20 3. Institute of Population Health Sciences, University of Liverpool, UK Division of
- 21 4.Neuroscience & Experimental Psychology, University of Manchester, UK Royal
- 22 Manchester Children's Hospital, Manchester, UK
- 23 5.Royal Manchester Children's Hospital, Manchester, UK Division of Evolution &
- 24 Genomic Sciences, University of Manchester, UK

Funding

25

29

- This project was funded by The Greater Manchester Health and Social Care
- 27 Partnership. The funders had no role in study design, data collection and analysis,
- decision to publish, or the preparation of the manuscript.

## Conflicts of interest

- RASM has received honoraria and support to attend international conferences from
- various pharmaceutical companies related to ADHD including Takeda, Flynn and
- Jannsen. RASM is also a non-paid advisor to various ASD, ADHD and FASD
- charities in England and Internationally (Australia and Europe). RASM has organised
- conferences and obtained non educational grants from various sources including
- Pharma and private hospitals. AP is an non-paid member of the Professional
- Advisory Panel of the not-for-profit organisation, ÉNDpae. All other authors declare
- 37 that they have no competing interests.

## 38 Acknowledgments

- We thank the parents, guardians, children, head teachers and staff at participant
- 40 schools. We also thank Róisín Reynolds and Rachael Nielsen from the Greater
- 41 Manchester Health and Social Care Partnership for their support. Philip May allowed
- 42 us to use the Maternal Risk Questionnaire, the University of New Mexico by the Fetal
- 43 Alcohol Syndrome Epidemiology Research Team initially developed in collaboration
- with Sharon Wilsnack (University of North Dakota), and adapted and updated
- 45 multiple times for use in prevalence studies in the United States, South Africa, and
- 46 Italy. We thank those who represented families affected by FASD, led by Anna

- Webster. We thank the members of an independent steering group, including Anna
- Webster Jen Michaels, Joanne Higham, Mary Scanlon and Susan McGrail.

**Abstract** 

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70 71

72

**Background:** Despite high levels of prenatal alcohol exposure in the UK, evidence on the prevalence of fetal alcohol spectrum disorders (FASD) is lacking. This paper reports on FASD prevalence in a small sample. Methods: A two-phase active case ascertainment study was conducted in three mainstream primary schools in Greater Manchester, UK. Schools were located in areas that ranged from relatively deprived to relatively affluent. Initial screening of children aged 8-9 years used pre-specified criteria for elevated FASD risk (small for age; special educational needs; currently/previously in care; significant social/emotional/mental health symptoms). Screen positive children were invited for detailed ascertainment of FASD using gold standard measures. Results: Of 220 eligible children, 50 (23%) screened positive and 12% (26/220) proceeded to phase-two assessment. Twenty had a developmental disorder, four had FASD and four were assessed as possible FASD. The crude prevalence rate of FASD in these schools was 1.8% (95%CI: 1.0%,3.4%) and when including possible cases was 3.6% (2.1%,6.3%). None of these children had previously identified with a developmental diagnosis. Conclusions: FASD was found to be common in these schools, but limitations to the sampling restrict inferences to a population prevalence. Most of these children's needs had not previously been identified. Keywords (5) FASD; Fetal Alcohol Syndrome (FAS); neurodevelopmental disorder; attention deficit hyperactivity disorder (ADHD); Autism Spectrum Disorder (ASD)

## Introduction

73

74 An estimated 10% of pregnancies globally are exposed to alcohol, a potent 75 teratogen that can lead to physical and neurodevelopmental birth defects (Popova et 76 al., 2017), collectively known as Fetal Alcohol Spectrum Disorders (FASD) (Cook et 77 al., 2016). FASD is an umbrella term that includes the diagnoses of Fetal Alcohol 78 Syndrome (FAS), pFAS (partial Fetal Alcohol Syndrome), ARBD (Alcohol-Related 79 Birth Defects), and ARND (Alcohol-Related Neurodevelopmental Disorder)/ND-PAE 80 (Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure). 81 The prevalence of FASD is 0.8% globally and highest in Europe, at 2% (Lange et al., 82 2017a). There are no direct estimates of prevalence in the four countries with the 83 highest known rates of prenatal alcohol exposure (Ireland, Belarus, Denmark and 84 UK), all of which have rates of over 40% pregnancies exposed to alcohol (Popova et 85 al., 2017). For the UK, the modelled estimate suggests 3.2% of children and young 86 people may have FASD (Lange et al., 2017a). Where a cohort with high levels of 87 exposure (79% of mothers drank during the pregnancy, with 25% at binge levels) 88 was used, 6-17% of children screened positive for features of FASD (McQuire et al., 89 2019). However, the lack of direct evidence of prevalence contributes to under-90 investment in diagnostic, treatment and prevention services (Scholin et al., 2021). 91 Active case ascertainment studies, the basis of global and national prevalence 92 estimates (Lange et al., 2017a), are considered the 'gold standard' method of 93 estimating prevalence, and involve screening a cross section of the general 94 population of children (Roozen et al., 2016). Passive methods are less useful 95 because individuals with FASD are often not diagnosed (May & Gossage, 2001; 96 Morleo et al., 2011) for a number of reasons, including a lack of knowledge/training

97 among healthcare/educational professionals (Mukherjee et al., 2015); difficulty in 98 differentiating features of FASD from other commonly co-occurring disorders (e.g. 99 Attention-Deficit/Hyperactivity Disorder, ADHD, or Autism Spectrum Disorder, ASD) 100 (Mukherjee et al., 2011: Young et al., 2016). 101 The aim of this study was to provide direct evidence of the prevalence of FASD in a 102 small sample of UK children aged 8 to 9 years. Materials and Methods 103 104 Setting 105 The setting was Greater Manchester, North West England (population 2.8 million), 106 an area with a higher than England average level of alcohol harm (Public Health 107 England, 2021), and relatively high deprivation (Ministry of Housing Communities 108 and Local Government, 2019). 109 This study was part of a wider initiative, the 'Preventing Alcohol Exposed Pregnancy 110 Programme' taking place in four of the ten Greater Manchester local authority areas. 111 The initiative also included increased awareness raising and interventions with 112 women who were pregnant or at risk of unplanned pregnancy (Reynolds et al., In 113 Press). 114 Design 115 We report on a cross-sectional study to detect cognitive impairments and associated 116 conditions, including FASD, using an Active Case Ascertainment method. Based on 117 the World Health Organization (WHO) standard protocol for FASD prevalence 118 studies (World Health Organisation, 2012), children in school year three/four (8-9 119 years of age at enrolment) who were able to communicate in English were invited to

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

take part in a two-phase approach. Children with a known risk factor for FASD went to the second phase (full assessment: Figure 1). Child assessments took place between July 2019 and March 2020. Restrictions related to the COVID-19 pandemic prevented face to face data collection from mid-March 2020, at which point there was one outstanding parent interview, which was conducted by telephone in March 2020. Sample size A sample size of 170 was adequate to get a preliminary indication of prevalence in a selected sample of schools (based on estimated true prevalence=0.03. precision=0.05; sensitivity=0.85; specificity=0.85). We aimed to recruit three schools (assuming approximately 60 pupils in the relevant age category per school). School recruitment In this pragmatic, small-scale study, schools were purposefully selected. Key informants (e.g. Heathy Schools Adviser, Education Psychologists) were consulted and suggested four schools, all of which agreed to take part. One school was excluded due to disengagement from the study and deviation from the protocol (see supplementary file 1 for details of a partial dataset). We initially aimed to include a specialist school providing Social Emotional and Mental Health (SEMH) support. All such schools within the study area were contacted. One such school agreed to take part but withdrew after being unable to gain consent from any parents. In February 2020, an extension of data collection was granted with the aim to recruit further schools to increase the baseline sample size. Four additional schools were recruited. However, the imposition of COVID-19 related restrictions, including

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

lockdown, meant that the study could not be completed in the second wave of schools. Partial results are reported in Supplementary file 1. Phase 1: Initial Screening Parents of all eligible children were sent a letter describing the study with the option to opt out, at least five days before data collection. Researchers were present in school to assess physical measurements. Height was measured using a mobile stadiometer, weight using Marsden MBF-6000 scales and head circumference (OFC) using a Sec 201 measuring tape. To become eligible for phase 2 (full assessment), one or more of the following criteria had to be met: height or weight below the ninth centile or OFC below the second centile; identified by the school or parents as having difficulties with learning, maladaptive behaviour, inattention or hyperactivity issues; have an Education Health and Care plan; be a currently or previously looked after child; already have diagnosed difficulties with behaviour including ADHD or conduct disorder. Exclusion criteria: disabilities or behavioural abnormalities known to be caused by well-characterised and already identified genetic factors (e.g. Down Syndrome, Williams Syndrome) or by post-natal brain injuries. These were excluded because the physical/behavioural stigmata overlap with FASD in presentation, and an FASD label cannot be attributed as the primary aetiological factor. Phase 2a: Measures completed by parents/carers Parents of those meeting criteria for phase 2 were sent information sheets and consent forms to opt themselves and their child into the study either by email, letter sent home, by telephone or in person by the Special Educational Needs Coordinator or head teacher. Where children were currently under the care of the local authority consent was obtained from the supervising social worker. For parent-report

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

assessments, most took place at school in a private room for two-hour sessions. Where requested by the parent, assessments took place in their home. Parent report assessments used the validated measures listed in Figure 1. The medical history was taken using a structured questionnaire developed originally at the University of New Mexico (May et al., 2011; May et al., 2018). The schedule included questions on pre-pregnancy, pregnancy and current substance use (alcohol, tobacco, prescription and illicit drugs), folic acid use in pregnancy and birth complications. General questions on current alcohol consumption were asked first as part of wider lifestyle set of questions, followed by questions about alcohol consumption in pregnancy. If alcohol was consumed during pregnancy, further questions ascertained the level and timing of consumption. Birth mothers were interviewed privately in order to encourage open reporting of alcohol use. For looked after children, fostered or adopted children, the parent/carer with most knowledge of the child was interviewed. Phase 2b: Measurements on children Measurements took place in school during school hours. Dysmorphology of fetal alcohol syndrome (FAS) facial characteristics was assessed from photographs (using standardised alignment of the participant's head relative to the camera lens) taken by trained researchers. Images were analysed by FAS Facial Photographic Analysis Software (Astley, 2015) and validated by an experienced clinical geneticist. Neurological impairment was assessed using the Developmental NEuroPSYchological Assessment (NEPSY) to assess memory, attention, and executive functions. The NEPSY subtests (Inhibition, Narrative Memory and Word List Interference, Animal Sorting, Clocks and Memory for Faces) were those that had been identified in previous FASD research (Rasmussen et al., 2013). The Wechsler

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

Intelligence Scale for Children (WISC V) (Kaufman et al., 2015) was used to assess the child's cognition, as used in previous FASD studies (Raldiris et al., 2018). Phase 2c: Ruling out genetic causes and case conference The results of the assessments were compared to the case definition (Table 1), derived from the WHO protocol for prevalence studies (World Health Organisation, 2012) and international guidelines (Cook et al., 2016). Where deficits met criteria in three subdomains, and PAE was present, FASD was considered. Where a child had all three sentinel facial features associated with FAS, FASD was considered in the absence of reported PAE. For all those considered for FASD, a Microarray Comparative Genomic Hybridisation (array CGH) test was used to rule out other disorders that may present with a similar behavioural presentation of genetic origin (Douzgou et al., 2012). A saliva sample was taken using the Oragene DNA OG-575 (DNAGenotek, 2020). The Oligo (Oxford Gene Technology, Oxford, UK) Hx60k array was carried out by the North Western Regional Genetics Laboratory within Manchester University NHS Foundation Trust, Manchester. Findings for each child discussed during case conferences attended by the study team including clinicians with expertise in the diagnosis of FASD. Cases of FASD were defined according to internationally recognised guidelines (Cook et al., 2016) and possible cases were cases where FASD was suspected but information was missing or unclear, for example regarding alcohol use. Data analysis Prevalence was estimated as the total number of children with FASD and probable FASD as the numerator, and the total number of eligible children at the same site as the denominator. This generates a conservative or minimum estimate of prevalence

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

as it assumed that all children who were not examined did not have FASD. To obtain confidence intervals we accounted for clusters (schools) by using nonparametric bootstrapping, resampling with replacement clusters with 10000 bootstrap runs. Ethical considerations Parents were invited to take part and were offered a report on their child's learning and behaviour issues, which could include a range of learning difficulties, including possible ASD, ADHD and FASD. The text of the information sheet made it clear that the main objective was to ascertain FASD prevalence. A small number of participants took part in genetic testing, which can occasionally identify markers for other health conditions. The information sheet sought to ensure that the parents/carers understood possible outcomes of the genetic test before giving consent. Ethical approval was granted by the University of Salford Ethics committee in May 2019 (reference: HSR1819-100). Results Participating schools Schools represented a range of deprivation when measured by the index of multiple deprivation. School 1 was located in one of England's 20% most deprived areas, and school 3, 30%. School 2 was located among the 20% most affluent areas in England. Flow of participants A total of 220 children were invited and 203 children took part in the phase 1 physical measures (height, weight and OFC) (Figure 2). Fifty children were eligible for full

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

assessment (phase 2) because of screening positive on the physical measures, parent/teacher concerns, already acknowledged as SEN, or currently or previously being in local authority care (Table 2). Full assessment took place with 26 children, four of whom had FASD and a further four were identified as possible FASD (Table 2). Other developmental disorders identified are detailed in supplementary file 2. Of the FASD cases, none had a prior clinical diagnosis of any neurodevelopmental disorder or an Education, Health and Care (EHC) Plan, and only one child had been identified by the school as having special educational needs. Three out of the four cases had high risk prenatal alcohol exposure reported, while in the fourth, alcohol was not reported but the child had severe FAS facial features, was small for age, a low full scale IQ of 66, and a normal CGH array (a summary of cases and possible cases assessed against the FASD criteria is given in supplementary file 2). Of the possible cases where FASD was suspected but not confirmed, none had a clinical diagnosis of any neurodevelopmental disorder and only one had an EHC Plan. All were on the schools' special educational needs register, had prenatal exposure to alcohol, and had deficits in at least three subdomains. Of the 12 children with a suspected disorder that was deemed unlikely to be FASD, 11 had some level of prenatal exposure to alcohol. Prevalence Rates We calculated a conservative (minimum) prevalence of FASD of 1.8% (95% CI [1.0, 3.4]), and a conservative (minimum) prevalence that also included possible FASD of 3.6% (95%CI [2.1, 6.3]) within our study population.

## Discussion

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Prevalence of FASD This is the first active case ascertainment study to be carried out in the UK, a country with one of the highest rates of drinking in pregnancy in the world. These prevalence estimates, though not necessarily generalisable to other communities, are in line with a modelled population prevalence estimate for the UK of 3.2% (Lange et al., 2017b) and consistent with a screening prevalence of 6-17% in a secondary analysis of data from a cohort study of children born in the 1990s (McQuire et al., 2019). As per May et al. (2018), our prevalence estimates could be considered as 'conservative' because we assumed all those who we did not fully assess did not have FASD. Further work examining the prevalence of FASD taking account of maternal sociodemographic factors and trends in alcohol consumption would allow a more precise estimate of the likely burden of this condition in the UK. The study region (Greater Manchester) sees approximately 34,000 babies born per year (ONS, 2020), yet diagnoses only around 36 cases of FASD per year (unpublished data from a Freedom of Information request). This low rate of diagnosis in relation to the example local prevalence we have demonstrated here suggests that increased recognition and diagnostic capacity is required. Alongside this, support for families affected by FASD is needed to prevent adverse secondary outcomes, such as school exclusions, poor job prospects and mental ill-health (Alex & Feldmann, 2012; Streissguth et al., 2004). Strengths and Limitations We demonstrated successful engagement with the three schools, who made intensive efforts on our behalf to recruit parents. The schools covered a range of

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

communities in different levels of deprivation, with two serving relatively deprived populations and one relatively affluent. A larger, more definitive study would use a random sampling technique, stratified by deprivation level, to select schools. We were unable to obtain sufficient information for almost half (24/50) of the children who were identified as being at higher risk of FASD. A further nine were actively withdrawn before phase 1 screening and selection took place. It is not possible to know whether the proportion of cases would have been higher or lower in these groups that did not take part. It is also possible that there were cases of FASD in the remaining 161 children with no apparent risk factors. It is possible the shame and stigma associated with FASD or developmental disorders in general may have impacted on participation. Extensive effort was made to contact each parent, and for those not taking part, the reasons were documented (see reasons given in Figure 2). The opportunity to have children's needs assessed was the major incentive for schools to take part in the study. For children in the care of foster parents, consent was required from the local authority and this was particularly difficult to obtain. We had initially hoped to include a further four schools in the prevalence calculations, however, disruptions due to COVID-19 prevented completion in these schools. Partial findings are presented in supplementary file 1. We were not successful in collecting data in a Social Emotional and Mental Health (SEMH) school despite recruiting an enthusiastic head teacher at such a school. Anecdotally, parents felt they had nothing to gain by taking part as their child was already benefiting from specialist support. Similarly, pupil referral units were not

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

included in this study. Together with SEMH schools, this is another setting where FASD prevalence is anticipated to be higher than the mainstream school setting. It is likely that prenatal alcohol exposure was underestimated in this study, as dose and duration of alcohol consumption during pregnancy was calculated from retrospective self-reporting, relying on recall of behaviours taking place 9 or 10 years prior. Social desirability bias also affects reporting of alcohol consumption during pregnancy (Smith et al., 2014) and we do not know how much the potential for perceived shame associated with alcohol consumption in pregnancy may have affected reporting. A general limitation in studies that measure the prevalence of FASD is that the only feature that is specific to damage caused by prenatal alcohol exposure is the distinctive facial appearance. However, significant facial features are thought to only occur in a minority of cases of FASD, and, likewise, in this study only two out of the eight cases and possible cases showed these distinctive features. We ruled out obvious genetic causes through chromosome microarray analysis and clinical geneticist review. However, it is not possible to prove that the alcohol exposure caused the deficits. The converse also true: it is not possible to rule out alcohol as an important causal factor. Every effort was taken to reduce bias that may give rise to false positives. The case definition used validated developmental assessments and was described in advance in the study protocol and followed internationally recognised guidance (Cook et al., 2016). An improvement on our methodology would have been to include a random sample of children for full assessment. This would have enabled us to obtain characteristics of the birth mothers in a group of children without any risk factors for FASD, which

would have allowed more sophisticated modelling (and extrapolation) of the likely prevalence in the entire population of 8-9 year olds (May et al., 2018). In this small-scale study, we determined that this would have been difficult. Parents were prepared to take part if they thought it might benefit their child, for example by getting more information to inform their special educational needs or to obtain a diagnosis. The fact that our assessment also identified possible ASD, ADHD and other neurodevelopmental conditions was a significant 'pull factor' for schools and parents. It was also notable that the only children actively opted into the study because of parent concerns (and no other risk factor) were from the school in the most affluent setting (school 2). Thus, motivations to take part may differ depending on socioeconomic status. We would conclude that further research would be needed into how to incentivise parents of children with apparently typical development to take part.

### Conclusions

This is the first study in the UK to directly assess FASD in a systematically ascertained sample of children. It found FASD in 1.8% (1.0%-3.4%) of the population studied, or 3.6% (2.1%,6.3%) when possible cases were also included. Due to the small sampling frame of schools included and limitations of baseline information obtained on contacted families, we can only conclude this represents local prevalence data in typical mainstream schools rather than being able confidentially to infer a 'population prevalence' of FASD. There are uncertainties too about this prevalence found, since half the children screened positive were lost to full ascertainment, and case identification may have been higher if all cases had been seen. It was already suspected from modelling and screening studies that FASD is highly prevalent in the UK (Lange et al., 2017a; McQuire et al., 2019). Confirmation

that this is the case in a sample of schools should be used to increase the awareness of FASD, and invest in diagnostic services, treatment and support for

those affected by FASD.

360

361

362

## References

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

Alex, K. & Feldmann, R. 2012. Children and adolescents with fetal alcohol syndrome (FAS): better social and emotional integration after early diagnosis. Klin Padiatr, 224, 66-71. Astley, S. J. 2015. Palpebral fissure length measurement: accuracy of the FAS Facial Photographic Analysis Software and inaccuracy of the ruler. Journal of Population Therapeutics and Clinical Pharmacology, 22(1). Cook, J. L., Green, C. R., Lilley, C. M., Anderson, S. M., Baldwin, M. E., Chudley, A. E., Conry, J. L., Leblanc, N., Loock, C. A., Lutke, J., Mallon, B. F., Mcfarlane, A. A., Temple, V. K. & Rosales, T. 2016. Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. Can. Med. Assoc. J., 188, 191-197. Dnagenotek 2020. Oragene 500-series. Genotek. Douzgou, S., Breen, C., Crow, Y. J., Chandler, K., Metcalfe, K., Jones, E., Kerr, B. & Clayton-Smith, J. 2012. Diagnosing fetal alcohol syndrome: new insights from newer genetic technologies. Arch. Dis. Child., 97, 812-817. Kaufman, A. S., Raiford, S. E. & Coalson, D. L. 2015. Intelligent testing with the WISC-V, USA, John Wiley & Sons. Lange, S., Probst, C., Gmel, G., Rehm, J., Burd, L. & Popova, S. 2017a. Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth A Systematic Review and Meta-analysis. *Jama Pediatr*, 171, 948-956.

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

Lange, S., Probst, C., Gmel, G., Rehm, J., Burd, L. & Popova, S. 2017b. Global Prevalence of Fetal Alcohol Spectrum Disorder Among Children and Youth: A Systematic Review and Meta-analysis. JAMA Pediatr, 171, 948-956. May, P. A., Chambers, C. D., Kalberg, W. O., Zellner, J., Feldman, H., Buckley, D., Kopald, D., Hasken, J. M., Xu, R., Honerkamp-Smith, G., Taras, H., Manning, M. A., Robinson, L. K., Adam, M. P., Abdul-Rahman, O., Vaux, K., Jewett, T., Elliott, A. J., Kable, J. A., Akshoomoff, N., Falk, D., Arroyo, J. A., Hereld, D., Riley, E. P., Charness, M. E., Coles, C. D., Warren, K. R., Jones, K. L. & Hoyme, H. E. 2018. Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities. *JAMA*, 319, 474-482. May, P. A., Fiorentino, D., Coriale, G., Kalberg, W. O., Hoyme, H. E., Aragon, A. S., Buckley, D., Stellavato, C., Gossage, J. P., Robinson, L. K., Jones, K. L., Manning, M. & Ceccanti, M. 2011. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: new estimated rates are higher than previous estimates. Int. J. Environ. Res. Public. Health, 8, 2331-51. May, P. A. & Gossage, J. P. 2001. Estimating the prevalence of fetal alcohol syndrome - A summary. *Alcohol Research & Health*, 25, 159-167. Mcquire, C., Mukherjee, R., Hurt, L., Higgins, A., Greene, G., Farewell, D., Kemp, A. & Paranjothy, S. 2019. Screening prevalence of fetal alcohol spectrum disorders in a region of the United Kingdom: A population-based birth-cohort study. Prev. Med., 118, 344-351. Ministry of Housing Communities and Local Government 2019. The English Indices of Deprivation. https://www.gov.uk/government/statistics/english-indices-ofdeprivation-2019.

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

Morleo, M., Woolfall, K., Dedman, D., Mukherjee, R., Bellis, M. A. & Cook, P. A. 2011. Under-reporting of foetal alcohol spectrum disorders: an analysis of hospital episode statistics. BMC Pediatr., 11. Mukherjee, R., Layton, M., Yacoub, E. & Turk, J. 2011. Autism and autistic traits in people exposed to heavy prenatal alcohol: data from a clinical series of 21 individuals and nested case control study. Advances in Mental Health and Intellectual Disabilities. Mukherjee, R., Wray, E., Curfs, L. & Hollins, S. 2015. Knowledge and opinions of professional groups concerning FASD in the UK. Adoption and Fostering, 39, 212-224. Ons 2020. Births in England and Wales: summary tables. Popova, S., Lange, S., Probst, C., Gmel, G. & Rehm, J. 2017. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. Lancet Global Health, 5, E290-E299. Public Health England 2021. Public Health Profiles. https://fingertips.phe.org.uk/search/alcohol%20specific%20death. Raldiris, T. L., Bowers, T. G. & Towsey, C. 2018. Comparisons of intelligence and behavior in children with fetal alcohol spectrum disorder and ADHD. Journal of attention disorders, 22 (10), 959-970. Rasmussen, C., Tamana, S., Baugh, L., Andrew, G., Tough, S. & Zwaigenbaum, L. 2013. Neuropsychological impairments on the NEPSY-II among children with FASD. Child Neuropsychology, 19, 337-349.

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

Reynolds, R., Mccarthy, R. & Cook, P. A. In Press. We do things differently here: the Greater Manchester approach to preventing alcohol-exposed pregnancy. Perspectives in Public Health. Roozen, S., Peters, G. J. Y., Kok, G., Townend, D., Nijhuis, J. & Curfs, L. 2016. Worldwide Prevalence of Fetal Alcohol Spectrum Disorders: A Systematic Literature Review Including Meta-Analysis. Alcoholism-Clinical and Experimental Research, 40, 18-32. Scholin, L., Mukherjee, R. a. S., Aiton, N., Blackburn, C., Brown, S., Flemming, K. M., Gard, P. R., Howlett, H., Plant, M., Price, A. D., Shields, J., Smith, L. A., Suttie, M., Zammitt, D. C., Cook, P. A. & Collaboration, U. F. R. 2021. Fetal alcohol spectrum disorders: an overview of current evidence and activities in the UK. Arch. Dis. Child. Smith, L., Savory, J., Couves, J. & Burns, E. 2014. Alcohol consumption during pregnancy: Cross-sectional survey. *Midwifery*, 30, 1173-1178. Streissguth, A. P., Bookstein, F. L., Barr, H. M., Sampson, P. D., O'malley, K. & Young, J. K. 2004. Risk factors for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J. Dev. Behav. Pediatr., 25, 228-38. World Health Organisation 2012. WHO Global Prevalence Study on FASD. WHO Research Initiative on Alcohol, Health and Development, WHO International Collaborative Research Project on Fetal Alcohol Spectrum Disorders (FASD). Young, S., Absoud, M., Blackburn, C., Branney, P., Colley, B., Farrag, E., Fleisher, S., Gregory, G., Gudjonsson, G. H., Kim, K., O'malley, K. D., Plant, M., Rodriguez, A., Ozer, S., Takon, I., Woodhouse, E. & Mukherjee, R. 2016. Guidelines for identification and treatment of individuals with attention

deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus. *BMC Psychiatry*, 16, 324.

# Table 1

461

462

463

# Table 1: Measures used and Fetal Alcohol Spectrum Disorder (FASD) domains

### of impairment

Domain	Sub-domain	Measure			
Growth		Height below 9 <sup>th</sup> percentile and Weight below 9 <sup>th</sup> percentile, medical history			
Ö					
Face		Photographic measurements 4 digit FAS Facial			
ш		Measurement software.			
	Brain	OFC below 2 <sup>nd</sup> centile, medical history or brain scan			
	Hard/ Soft	report  SSP Defined differences in 2 or more domains			
	Neurological signs				
	Neurological signs	History of formally diagnosed motor disorder e.g.			
		dyspraxia  History of epilepsy or other neurological issues (from			
ε		medical history)			
Syste	Communication	CCC-2, Vineland communication domain. Defined by			
Central Nervous System		abnormality >1.5 standard deviations below the mea			
N N N N	Cognition	WISC V: IQ 2 standard deviations from norm or 2			
Centra		standard deviations between different subdomains			
	Executive Function	BRIEF overall score: Score above clinical cut off			
		range			
		NEPSY executive function domain Score 1.5			
		standard deviations from norm or 2 standard			
		deviations between subdomains			
	Memory	WISC V, NEPSY Memory domain			

	Attention	SDQ attention domain scores above clinical cut offs
		NEPSY attention domain
	Adaptive behaviour,	SCQ (score above 15), SDQ (score above clinical cut
	social skills	off), Vineland Social domain, Vineland Daily Living
		Skills domain (both scores 1.5 standard deviations
		from mean)
	Academic	Teacher report, below average level, has EHC Plan
Alcohol consumption of birth		History information sheet
mother		

BRIEF: Behaviour Rating Inventory of Executive Function

CCC-2: Communication Checklist for Children

467 EHC Plan: Education Health and Care Plan

468 NEPSY: NEuroPSYchological Assessment

OFC: Occipitofrontal Circumference

470 SSP: Short Sensory Profile

471 SCQ: Social Communication Questionnaire

472 SDQ: Strengths and Difficulties Questionnaire

473 WISC-V: Wechsler Intelligence Scale for Children Fifth UK Edition

## Table 2

464

466

469

474

475

### Table 2: Screening and assessment data by school

	School1 (baseline N=44)	School2 (baseline N=118)	School3 (baseline N=59)	Total (N=220)
Screened at stage one n (% of baseline)	38 (86)	109 (92)	56 (95)	203 (92)
Sex, n(% of baseline)				

Male	18 (40)	55 (46)	30 (51)	103 (47)		
Female	20 (45)	54 (46)	26 (44)	100 (45)		
Age, Years (y) & months (m)	` ,	, ,	, ,	, ,		
Median	8y11m	8y10m	8y6m	8y10m		
[Interquartile range]	[8y9m, 9y5m]	[8y5m, 9y6m]	[8y3m, 8y11m]	[8y 5m, 9y4m]		
(range)	(8y3m, 9y9m)	(8y0m, 9y10m)	(8y0m, 9y8y)	(8y0m, 9y10m)		
Physical screen						
positive						
n (% of baseline)						
Height <9 <sup>th</sup> percentile	4 (9)	7 (6)	2 (3)	13 (6)		
Weight <9 <sup>th</sup> percentile	2 (5)	3 (3)	2 (3)	7 (3)		
OFC <2th percentile	1 (2)	1(1)	1 (2)	3 (1)		
Reason for recruitment n (% of invited)						
SEN	14(66)	7 (43)	5 (50)	26 (13)		
SFA	3(14)	5 (31)	4 (40)	12 (6)		
LAC	2(10)	3 (18)	1 (10)	6 (3)		
SFA+SEN	2(10)	0	0	2 (1)		
SFA + prevLAC	2(10)	1 (6)	0	1 (0.5)		
Parent opt-in	0	3 (16)	0	3 (1)		
•		0 (10)		• ( · )		
Invited to second	24	10	10	50		
Invited to second phase	21	19	10	50		
	21 <b>N=10</b>	19 <b>N=9</b>	10 <b>N=7</b>	50 <b>N=26</b>		
phase Phase two						
phase Phase two assessments Referral reason (% of						
phase Phase two assessments Referral reason (% of phase two participants)	N=10	N=9	N=7	N=26		
phase Phase two assessments Referral reason (% of phase two participants) SEN	N=10 5 (50)	N=9 3 (33)	<b>N=7</b> 4 (57)	<b>N=26</b> 12 (46)		
phase Phase two assessments  Referral reason (% of phase two participants)  SEN SFA	N=10 5 (50) 3 (30)	<b>N=9</b> 3 (33) 0	<b>N=7</b> 4 (57) 2 (29)	<b>N=26</b> 12 (46) 5 (19)		
phase Phase two assessments Referral reason (% of phase two participants) SEN SFA LAC	5 (50) 3 (30) 0	N=9 3 (33) 0 2 (22)	<b>N=7</b> 4 (57) 2 (29) 1 (14)	N=26  12 (46) 5 (19) 3 (12)		
phase Phase two assessments Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN	N=10  5 (50) 3 (30) 0 2 (20)	N=9 3 (33) 0 2 (22) 0	<b>N=7</b> 4 (57) 2 (29) 1 (14) 0	N=26  12 (46) 5 (19) 3 (12) 2 (8)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%)	N=10  5 (50) 3 (30) 0 2 (20) 0 0	N=9  3 (33)  0 2 (22)  0 1 (11)	<b>N=7</b> 4 (57) 2 (29) 1 (14) 0 0	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%) White UK	5 (50) 3 (30) 0 2 (20) 0	N=9  3 (33)  0 2 (22)  0 1 (11)	<b>N=7</b> 4 (57) 2 (29) 1 (14) 0 0	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%)	N=10  5 (50) 3 (30) 0 2 (20) 0 0	N=9  3 (33) 0 2 (22) 0 1 (11) 3 (33)	N=7  4 (57) 2 (29) 1 (14) 0 0 0	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4) 3 (11)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%) White UK	5 (50) 3 (30) 0 2 (20) 0 0	N=9  3 (33) 0 2 (22) 0 1 (11) 3 (33) 8 (89)	N=7  4 (57) 2 (29) 1 (14) 0 0 0 6 (86)	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4) 3 (11)  24 (92)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%) White UK Non white	N=10  5 (50) 3 (30) 0 2 (20) 0 0 10 (100) 0	N=9  3 (33) 0 2 (22) 0 1 (11) 3 (33)  8 (89) 1 (11)	N=7  4 (57) 2 (29) 1 (14) 0 0 0 6 (86) 0	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4) 3 (11)  24 (92) 1 (4)		
Phase two assessments  Referral reason (% of phase two participants) SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%) White UK Non white Not reported  Maternal educational qualifications, highest	N=10  5 (50) 3 (30) 0 2 (20) 0 0 10 (100) 0	N=9  3 (33) 0 2 (22) 0 1 (11) 3 (33)  8 (89) 1 (11)	N=7  4 (57) 2 (29) 1 (14) 0 0 0 6 (86) 0	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4) 3 (11)  24 (92) 1 (4)		
Phase two assessments  Referral reason (% of phase two participants)  SEN SFA LAC SFA and SEN SFA and PrevLAC parent opt in  Maternal Ethnicity, n(%) White UK Non white Not reported  Maternal educational qualifications, highest received n(%)	N=10  5 (50) 3 (30) 0 2 (20) 0 0 10 (100) 0 0	N=9  3 (33) 0 2 (22) 0 1 (11) 3 (33)  8 (89) 1 (11)	N=7  4 (57) 2 (29) 1 (14) 0 0 0 6 (86) 0 1 (14)	N=26  12 (46) 5 (19) 3 (12) 2 (8) 1 (4) 3 (11)  24 (92) 1 (4) 1 (4)		

Degree	2 (20)	4 (44)	2 (29)	8 (30)		
Missing data	0	2 (22)	1 (14)	3 (12)		
Full assessment						
Deficits in three						
subdomains met, n(% of	8 (80)	7 (78)	6 (86)	21 (80)		
assessed)						
FASD, n (% of assessed)						
FASD	1 (10)	3 (33)	0 (0)	4 (15)		
FASD and possible FASD	3 (30)	4 (44)	1 (10)	8 (30)		
Other outcomes						
ASD	0 (0)	2 (22)	3 (43)	5 (19)		
ADHD	2 (20)	0 (0)	1 (14)	3 (12)		
DLD	2 (20)	1 (10)	0 (0)	3 (12)		
General learning disability	0 (0)	0 (0)	2 (28)	2 (8)		
No disorder	3 (30)	2 (20)	0 (0)	5 (19)		
FASD prevalence per 100 [95% CI]						
FASD	2.3 [0.3,14.8]	2.5 [0.8, 7.4]	No observations	1.8 [1.0,3.4]		
FASD and possible FASD	7.0 [2.2,19.8]	3.4 [1.3, 8.7]	1.7 [0.2,11.1]	3.6 [2.1,6.3]		

SEN: on school educational needs register; SFA: small for age; LAC: 'looked after

477 child', i.e. under care of local authority; PrevLAC: previously looked after child, i.e.

adopted; OFC: occipital frontal circumference; GCSE: General Certificate of

Education, qualification usually taken at age 16 years; A level: Advanced Level,

qualification usually taken at age 18 years; FASD: fetal alcohol spectrum disorder;

ASD: autism spectrum disorder; ADHD: attention deficit hyperactivity disorder; DLD:

developmental language disorder.

478

479

480

481

482

483

484

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506


507

developmental language disorder.

Table legends Table 2: Measures used and Fetal Alcohol Spectrum Disorder (FASD) domains of impairment BRIEF: Behaviour Rating Inventory of Executive Function CCC-2: Communication Checklist for Children EHC Plan: Education Health and Care Plan NEPSY: NEuroPSYchological Assessment OFC: Occipitofrontal Circumference SSP: Short Sensory Profile SCQ: Social Communication Questionnaire SDQ: Strengths and Difficulties Questionnaire WISC-V: Wechsler Intelligence Scale for Children Fifth UK Edition Table 2: Screening and assessment data by school SEN: on school educational needs register; SFA: small for age; LAC: 'looked after child', i.e. under care of local authority; PrevLAC: previously looked after child, i.e. adopted; OFC: occipital frontal circumference; GCSE: General Certificate of Education, qualification usually taken at age 16 years; A level: Advanced Level, qualification usually taken at age 18 years; FASD: fetal alcohol spectrum disorder; ASD: autism spectrum disorder; ADHD: attention deficit hyperactivity disorder; DLD:

Figure legends Figure 1. Study design Figure 2. Flow of participants through the study. SFA: small for age; SEN: on school educational needs register; LAC: 'looked after child' i.e. in the care of the local authority; PrevLAC: previously looked after, i.e. adopted. 

Figure 1



Initial screening with children (participation on the basis of attendence at school on the measurement days and no parental opt out)

Height, Weight and Occipitofrontal measurement

All children screened positive at step 1 invited to step two and either:

small / small head (occipitofrontal) circumference (OFC)

and/or identified as SEN
or teacher-identified /parent-identified behaviour problem or learning diff

and/or teacher-identified /parent-identified behaviour problem or learning difficulty and/or looked after child

#### PHASE 2a: Parent Assessment

Parent opt-in required, assessed with parent/teacher-completed measurement tools:

Social Communication Questionnaire (SCQ)

Strengths and Difficulties Questionnaire (SDQ)

Short Sensory Profile (SSP)

Vineland Adaptive Behavior Scales II (VABS-II)

Communication checklist for children (CCC-2)

Medical History sheet

### PHASE 2b: Child Assessment

child assessed for (child-completed)

Cognitive (WISC V and NEPSY)

face morphology (photography)

### PHASE 2c

### genetic testing

(rule out genetic causes)

### case conference

children fully meet criteria for FASD

or possible cases

Figure 2

